¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Early Growth Response Transcription Factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® growth hormone ÇÑ±Û ¼ºÀåÈ£¸£¸ó
¼³¸í   
  ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼­ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀڱصǸ砼Ҹ¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼­ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŰ¸ç Æ¯È÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇϴ °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼­ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇ̵Ǹ頼ºÀåºÎÁøÀÌ ¿Â´Ù.
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reverse transcription
    ¿ªÀü»ç
  • early ambulation
    Á¶±âº¸Çà
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early neonatal mortality rate
    Á¶±â½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â¼ö¿ëüÀüÀ§, Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early syphilis
    Ãʱâ¸Åµ¶
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early ambulation
    Á¶±âº¸Çà
  • growth factor
    ¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • peak growth velocity
    Ãִ뼺Àå¼Óµµ
  • growth zone
    ¼ºÀ屸¿ª
  • response curve
    ¹ÝÀÀ°î¼±
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • response
    ¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reverse transcription
    ¿ªÀü»ç
  • transcription
    ˟ȍ
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early reaction
    Á¶±â¹ÝÀÀ
  • early syphilis
    Ãʱâ¸Åµ¶, Á¶±â¸Åµ¶
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
  • apical growth
    ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • asynchronous growth
    ºñµ¿Á¶Áõ½Ä
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
  • immediate early gene
    Á¶±â ¹ßÇö À¯ÀüÀÚ
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • BERA =Brainstem Evoked Response Audiometry
    ³ú°£À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • Fast response
    ±Þ¼Ó(ÐááÜ)¹ÝÀÀ(Úãëë)
  • Inflammatory response
    ¿°Áõ¹ÝÀÀ(æúñøÚãëë)
  • Lewis triple response
    ·çÀ̽º »ïÁß ¹ÝÀÀ
  • MAC-BAR(minimum alveolar concentration-blockade of autonomic response)
    ÀÚÀ²½Å°æ¾ïÁ¦ ÃÖ¼ÒÆóÆ÷³»³óµµ
  • allergic response
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • analytical response detection
    ºÐ¼®¹ÝÀÀ°¨Áö
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • approximate response
    ±Ù»ç¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tissue growth factors
  • chimeric transcription tactor
  • leader RNA primed transcription
    ¼±µµ RNA ½Ã¹ßÀü»ç
  • reverse transcription
    ¿ªÀü»ç
  • reverse transcription
    ¿ªÀü»ç(æ½ï®ÞÐ).
  • transcription
    ˟ȍ
  • transcription factor
    Àü»çÀÎÀÚ
  • transcription factor II
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(èâì×àõ é©áÈ).
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(¡­é©áÈ).
  • factors
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Appositional growth
    µ¡ºÙÀ̼ºÀå
    [¿¾ ¿ë¾î] ÷°¡¼ºÀå
  • Abnormal growth
    ºñÁ¤»ó¼ºÀå
    [¿¾ ¿ë¾î] ºñÁ¤»ó¼ºÀå
  • Interstitial growth
    »çÀÌÁú¼ºÀå
    [¿¾ ¿ë¾î] °£Áú¼ºÀå
  • Growth abnormality
    ¼ºÀåÀÌ»ó
    [¿¾ ¿ë¾î] ¼ºÀåÀÌ»ó
  • Growth defect
    ¼ºÀå°áÇÔ
    [¿¾ ¿ë¾î] ¼ºÀå°áÇÔ
  • Growth cone
    ¼ºÀå¿ø»Ô
    [¿¾ ¿ë¾î] ¼ºÀå¿øÃß
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • suppressor factors
    ¾ï¾Ð(ÀÚ) ÀÎÀÚ(åääâ(í­)ì×í­)
  • early enzyme
    Á¶±â È¿¼Ò(ðÄÑ¢ý£áÈ)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • early protein
    Á¶±â ´Ü¹éÁú (ðÄÑ¢Ó±ÛÜòõ)
  • early RNA
    Á¶±â(ðÄÑ¢) RNA
  • immediate early RNA
    ÃÖÁ¶±â(õÌðÄÑ¢) RNA
  • very early RNA
    ÃÊÁ¶±â(õ±ðÄÑ¢) RNA
  • asymmetric transcription
    ºÒ±Õµî Àü»ç (ÝÕгÔõï®ÞÐ)
  • coupled transcription-translation
    µ¿½Ã Àü»ç¹ø¿ª(ÔÒãÁï®ÞÐÛèæ»)
  • divergent transcription
    ºÐÁö Àü»ç(ÝÂò«ï®ÞÐ)
  • reverse transcription
    ¿ªÀü»ç(æ½ï®ÞÐ)
  • rRNA transcription unit
    rRNA Àü»ç ´ÜÀ§(ï®ÞÐÓ¤êÈ)
  • symmetric transcription
    ´ëĪÀü»ç (Óßöàï®ÞÐ)
  • transcription
    Àü»ç(ï®ÞÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • quality factors
    Ư¼º¿ä¼Ò, Áú¿ä¼Ò
  • transcription
    º¹»ç, Àü»ç
  • early diagnosis
    Á¶±âÁø´Ü
  • early gastric cancer
    Á¶±âÀ§¾Ï
  • response
    ¹ÝÀÀ, ÀÀ´äÀÇ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • growth
    ¼ºÀå
  • growth abnormality
    ¹ßÀ°ÀÌ»ó
  • growth and development
    ¼ºÀå°ú ¹ßÀ°
  • growth arrest line
    ¼ºÀåÁö¿¬¼±
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth line
    ¼ºÀå¼±
  • growth retardation
    ¼ºÀåÁö¿¬
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
AER abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
EGR early growth response; erythema gyratum repens
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Egr Early Growth Response
Egr-1 Early Growth Response factor 1
EGR1 early growth response 1 gene
Egr-1 Early growth response-1
VETF virus early transcription factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • reverse transcription
    ¿ªÀü»ç
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • amblyopia of early arrest
    Á¶±â Á¤Áö ¾à½Ã
  • early ambulation
    Á¶±â ¿îµ¿ ½ÃÀÛ
  • early assessment
    ÃÊ±â Æò°¡
  • early childhood
    Ãʱ⠾Ƶ¿±â
    ¸¸ 1-6¼¼ ±îÁöÀÇ ½Ã±â.
  • early clinical symptom
    Ãʱâ ÀÓ»ó Áõ»ó
  • early closing clicking joint noise
    Æó±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ ÈĹæ ȰÁÖ ¿îµ¿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
  • early diagnosis
    Á¶±â Áø´Ü
    º´ÀÇ ÁøÇà¿¡ ¾Õ¼­ Áø´ÜÇÏ¿© ´ëÃ¥À» ¼¼¿ò, ¿ÏÀü Ä¡À¯ ±â´ë.
  • early distal tubule
    Ãʱ⠿øÀ§ ¼¼´¢°ü
  • early gestation
    ÀӽŠÃʱâ
  • early melanoma
    Ãʱâ Èæ»öÁ¾
    ¸á¶ó´Ñ ¼¼Æ÷ÀÇ ¾Ç¼º Á¾¾ç¿¡ Ãʱ⠴ܰè. Á¾Á¾ ¾ç¼º ¸ð¹ÝÀ¸·Î ¿ÀÇØµÈ´Ù. ±¸°­¿¡¼­ °¡Àå ÈçÇÑ Èæ»öÁ¾Àº Ç¥Ãþ È®À强 Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾, ¸»´ÜÈæ»öÁ¾À¸·Î ³ª´µ¾îÁø´Ù. ¿¹Èİ¡ ³ª»Ú´Ù.
  • early nodular melanoma
    Ãʱ⠼ҰáÀý¼º Èæ»öÁ¾
  • early opening clicking joint noise
    °³±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ Àü¹æ ȰÁֿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
transcription factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
(12 Dec 1998)
transcription factors, tfii The so-called general transcription factors that bind to RNA polymerase II and that are required to initiate transcription. They include tfiia, tfiib, tfiid, tfiie, tfiif, tfiih, tfii-I, and tfiij. In vivo they apparently bind in an ordered multi-step process and/or may form a large preinitiation complex called RNA polymerase II holoenzyme.
(12 Dec 1998)
transcription factors, tfiii Factors that bind to RNA polymerase III and aid in transcription. They include the assembly factors tfiiia and tfiiic and the initiation factor tfiiib. All combine to form a preinitiation complex at the promotor that directs the binding of RNA polymerase III.
(12 Dec 1998)
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
B-cell differentiation/growth factors Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells.
(05 Mar 2000)
growth factors Proteins involved in cell differentiation and growth.Growth factors are essential to the normal cell cycle, and are thus vital elements in the life of animals from conception to death. Among other things, they mediate foetal development, play a role in maintenance and repair of tissues, stimulate production of blood cells, and, gone awry, participate in cancerous processes.
(05 Mar 2000)
haematopoietic cell growth factors These growth factors comprise a family of haematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. Erythropoietin and the colony-stimulating factors belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.
(12 Dec 1998)
stem cell growth factors <growth factor> Compounds, usually proteins, that make stem cells grow faster.
(26 Mar 1998)
nerve growth factors Factors which enhance the growth potentialities of sensory and sympathetic nerve cells.
(12 Dec 1998)
insulin-like growth factors Peptides whose formation is stimulated by growth hormone. These peptides bring about peripheral tissue effects of that hormone and have high (about 70%) homology to human insulin.
Synonym: somatomedins.
(05 Mar 2000)
transforming growth factors <chemical> Hormonally active polypeptides that can induce the transformed phenotype when added to normal, non-transformed cells. They have been found in culture fluids from retrovirally transformed cells and in tumour-derived cells as well as in non-neoplastic sources. Their transforming activities are due to the simultaneous action of two otherwise unrelated factors, transforming growth factor alpha and transforming growth factor beta.
Chemical name: Animal growth regulators, transforming growth factors
(12 Dec 1998)
endothelial growth factors These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesise DNA. The factors are related to both the basic and acidic fibroblast growth factors but have different amino acid sequences.
(12 Dec 1998)
reverse transcription <molecular biology> The process of copying information found in RNA into DNA.
(09 Oct 1997)
transcription <molecular biology> Synthesis of RNA by RNA polymerases using a DNA template.
(18 Nov 1997)
transcription factor <molecular biology> Protein required for recognition by RNA polymerases of specific stimulatory sequences in eukaryotic genes.
Several are known that activate transcription by RNA polymerase II when bound to upstream promoters.
Transcription of the 5S RNA gene in Xenopus by RNA polymerase III is dependent on a 40 kD protein TFIIIA that binds to a regulatory site in the centre of the gene and was the first protein found to exhibit the metal binding domains known as zinc fingers.
(17 Mar 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Early Growth Response Transcription Factors - »õâ A family of transcription factors that are induced by GROWTH FACTORS and contain a highly conserved DNA-binding domain composed of three ZINC FINGER MOTIFS.
    Synonyms : EGR Transcription Factors, Transcription Factors, EGR
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transcription
    ˟ȍ
  • electrical transcription
    ³ìÀ½ ¹æ¼Û¿ä(·¹ÄÚµå,Å×ÀÌÇÁ);³ìÀ½
  • transcription
    ÇÊ»ç;¸ð»ç;º¹»ç;¹Ù²ã ¾¸;Àü»ç;¹Ù²ã¾´ °Í
  • growth
    ¼ºÀå,¹ß´Þ,Áõ°¡
  • response
    ÀÀ´ä
  • conditioned reflex (response)
    Á¶°Ç ¹Ý»ç
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • flexible response
    ½ÅÃàÀû ´ëÀÀ(1967³â NOTO°¡ ¹Ù¸£»þ¹Ù Á¶¾à±º¿¡ ´ëÇØ¼­ äåÇÑ Àü·«)
  • flexible response
    ½ÅÃàÀû´ëÀÀ
  • frequency response
    Á֯ļöÀÀ´ä
  • galvanic skin response
    Àü±â ÇǺΠ¹ÝÀÀ(°ÅÁþ¸» ŽÁö±â¿¡ ÀÀ¿ë)
  • growth
    ¼ºÀå;»ýÀå;¹ßÀ°;¹ß´Þ;Áõ´ë;Àç¹è;»ýÀå(¹ß»ý)¹°;»ê¹°
  • growth center
    (sensitivity trainingµîÀ»ÇÏ´Â)´É·Â °³¹ß ¼¾ÅÍ)
  • growth hormone
    ¼ºÀå È£¸£¸ó 
  • growth industry
    ¼ºÀå »ê¾÷
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á